Ajanta Pharma Limited (BOM:532331)
India
· Delayed Price · Currency is INR 2,584.35
-116.50 (-4.31%)
At close: May 2, 2025
Ajanta Pharma Revenue
In the fiscal year ending March 31, 2025, Ajanta Pharma had annual revenue of 46.48B INR with 10.44% growth. Ajanta Pharma had revenue of 11.70B in the quarter ending March 31, 2025, with 11.04% growth.
Revenue
46.48B
Revenue Growth
+10.44%
P/S Ratio
6.95
Revenue / Employee
5.76M
Employees
8,073
Market Cap
322.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 46.48B | 4.39B | 10.44% |
| Mar 31, 2024 | 42.09B | 4.66B | 12.45% |
| Mar 31, 2023 | 37.43B | 4.02B | 12.02% |
| Mar 31, 2022 | 33.41B | 4.51B | 15.62% |
| Mar 31, 2021 | 28.90B | 3.02B | 11.66% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,646.93B |
| HDFC Bank | 2,728.47B |
| Tata Consultancy Services | 2,553.24B |
| Bharti Airtel | 1,627.08B |
| ICICI Bank | 2,006.54B |
| State Bank of India | 3,409.52B |
| Infosys | 1,647.16B |
| Bajaj Finance | 369.88B |
Ajanta Pharma News
- 4 days ago - Ajanta Pharma Q4 Results: Net profit grows 11% YoY to Rs 225 crore, EBITDA Margin at 25% - Business Upturn
- 19 days ago - Stocks to buy today on brokerages’ call: IndiGo, Ajanta Pharma, TBO, HDFC Bank, Vodafone Idea among top picks – Check investment target - Business Upturn
- 19 days ago - Jefferies initiates Buy on Ajanta Pharma, sees 11% upside due to strong presence in branded generics markets - Business Upturn
- 19 days ago - Stocks to watch today: Interglobe Aviation, Ajanta Pharma, HDFC Bank, Vodafone Idea, Hindalco, TBO, L&T in focus on brokerage reports - Business Upturn
- 3 months ago - Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, PAT Up 11% to Rs 233 crore - Business Upturn
- 5 months ago - Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27% - Business Upturn
- 6 months ago - Ajanta Pharma declares first interim dividend of ₹28 per share for FY25 - Business Upturn
- 6 months ago - Ajanta Pharma Q2 FY25 Results: Revenue rises 15% to ₹1,187 crore, net profit grows 11% to ₹216 crore - Business Upturn